Venetoclax

WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer with over 40 years of experience inventing, advancing development for, and securing approvals of novel medicines including multiple blockbusters. “Rob has played a central role in bringing some of the industry’s most important medicines, including dermatology and immunology therapies, to the world, and we are excited to welcome him to our board,” said Frank Watanabe, president and CEO of Arcutis. “Rob’s deep experience taking novel medicines from development through approval will be invaluable as we advance our pipeline and work to bring meaningful innovation to people living with chronic inflammatory skin diseases.” “Arcutis is at an exciting stage of growth, with strong adoption of ZORYVE and a growing pipeline of potential new ZORYVE indications and a novel biologic,” said Rob Scott, MD. “Individuals with chronic skin diseases still need better treatment options, and I look forward to working with the management team and board to help deliver them.“ Dr. Scott was formerly the Chief Medical Officer at AbbVie where he had responsibility for approximately 40 new molecular entities and 4,000 team members before retiring in 2020. During his tenure, AbbVie achieved over 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi, and Rinvoq. He also created the Development Design Center, a Center of Excellence focused on using AI, predictive analytics, and big data to design and implement better clinical trials. Previously, he served as the vice president of global development at Amgen, where he accelerated and achieved the approval of Repatha, a PCSK9 inhibitor for the treatment of cardiovascular disease. Dr. Scott was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and participated as a committee member fourteen times. Earlier in his career while at Pfizer, he developed Lipitor and Norvasc. He invented and developed the first commercially available Polypill - Caduet. In addition, at AtheroGenics, he conducted the first large cardiovascular outcomes study to be wholly performed by a small biotech. Rob has sat on multiple public and private boards, as well as scientific and strategic advisory boards. Dr. Scott is a Zimbabwean-born physician and a graduate of the University of Cape Town. INDICATIONSZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older. ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. IMPORTANT SAFETY INFORMATION ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application. The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%). The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%). The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%). The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%). The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%). Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the Company's growth, advancement of its development pipeline, and future business prospects. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Contacts:MediaAmanda Sheldon, Head of Corporate Communicationsmedia@arcutis.com InvestorsBrian Schoelkopf, Head of Investor Relationsir@arcutis.com https://www.globenewswire.com/NewsRoom/AttachmentNg/1f35cf6b-9e1e-4dbc-a86f-9f3cb15b5db1.

急性髓系白血病（AML）是一种高度异质性的血液系统恶性肿瘤，具有复发率高、预后不良等特点。白血病干细胞（LSCs）是驱动AML发生、疾病复发和治疗耐药的重要根源，高效清除LSCs是实现AML长期缓解的关键。 LSCs主要依赖线粒体氧化磷酸化（OXPHOS）维持能量代谢，这一过程不可避免地产生活性氧（ROS）。然而，LSCs能够通过强大的抗氧化防御系统维持较低的ROS水平，从而避免氧化应激损伤并保持其自我更新能力和恶性潜能。目前，LSCs如何协调线粒体能量代谢与氧化还原稳态，其关键分子调控机制仍不清楚。因此，鉴定维持LSCs氧化还原稳态的关键靶点，对于开发克服AML治疗耐药的新策略具有重要意义。 近日，重庆医科大学人工智能学院赵雪雅副教授联合基础医学院陈哲副教授、侯宇教授在Nature Communications杂志发表了题为 NYNRIN safeguards leukemia stem cells by sustaining thioredoxin activity to maintain redox homeostasis 的研究论文。该研究鉴定出NYNRIN是维持白血病干细胞生存和自我更新的关键调控因子，揭示了NYNRIN通过直接结合并降解TXNIP mRNA，维持硫氧还蛋白（Trx）活性及细胞氧化还原稳态的全新机制。同时发现，靶向NYNRIN能够增强BCL2抑制剂维奈克拉（Venetoclax）的抗白血病作用，为AML的精准干预及克服治疗耐药提供了新的潜在策略。 在本研究中，研究团队通过多组学数据库分析及临床样本验证，发现NYNRIN在LSC样细胞中高表达，且与AML患者不良预后密切相关。在MLL-AF9和HOXA9/MEIS1驱动的AML小鼠模型及患者来源异种移植（PDX）模型中，NYNRIN缺失或敲低显著削弱LSCs的自我更新能力，抑制白血病进展并延长荷瘤小鼠生存期。值得注意的是，NYNRIN杂合缺失即可有效抑制LSCs的维持，而对正常造血干细胞影响相对有限，提示其具有潜在的选择性干预窗口。 机制探索方面，研究团队发现NYNRIN作为RNA结合蛋白，通过其NYN结构域直接结合并促进TXNIP mRNA降解，从而抑制TXNIP表达，维持Trx的抗氧化活性，促进ROS清除并保护LSCs免受氧化应激损伤。相反，NYNRIN缺失导致TXNIP积累，抑制Trx活性，引发ROS过度产生、线粒体功能障碍及LSCs凋亡。这一发现揭示了NYNRIN通过转录后调控维持氧化还原稳态的全新功能，确立了NYNRIN-TXNIP-Trx信号轴在LSCs存活中的关键作用。 针对AML治疗中LSCs难以彻底清除及维奈克拉耐药等问题，研究团队进一步探索了靶向NYNRIN的治疗潜力。研究发现，NYNRIN缺失能够破坏LSCs的抗氧化防御系统，降低其凋亡阈值，从而增强BCL2抑制剂维奈克拉的抗白血病作用。在AML细胞及动物模型中，NYNRIN抑制联合维奈克拉显著增强白血病细胞凋亡并抑制LSCs维持，提示靶向NYNRIN可能成为提高维奈克拉疗效的新策略。 综上，该研究确立了NYNRIN作为白血病干细胞关键生存依赖因子的作用，揭示了NYNRIN通过降解TXNIP mRNA、维持Trx活性及氧化还原稳态保护LSCs的全新分子机制，并证明抑制NYNRIN能够增强维奈克拉的抗白血病作用，为靶向LSCs及AML联合治疗提供了新的理论依据和潜在干预靶点。 全文链接： https://doi.org/10.1038/s41467-026-78678-4 学术合作组织 （*排名不分先后） 战略合作伙伴 （*排名不分先后） · 推荐直播 · 转载须知 【非原创文章】本文著作权归文章作者所有，欢迎个人转发分享，未经作者的允许禁止转载，作者拥有所有法定权利，违者必究。 BioArt Med Plants 人才招聘 点击主页推荐活动 关注更多最新活动！